Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.80 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.79 |
| ▸ | FLT3 | P36888 | 1/20 | 0.79 |
| ▸ | BLK | P51451 | 1/20 | 0.79 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.79 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.79 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19208011 | 1.00 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327317 | 0.92 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208028 | 0.92 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208017 | 0.92 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208012 | 0.91 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208013 | 0.90 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL29632362 | 0.89 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936243 | 0.89 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1975451 | 0.88 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL29371799 | 0.88 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| WO-2025082484-A1 | TREATMENT OF PATIENT WITH NEGATIVE P53 GENE MUTATION, POSITIVE KRAS GENE MUTATION AND POSITIVE BRCA MUTATION | 深圳艾欣达伟医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | disclosed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |